Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBT Margin (2016 - 2025)

Historic EBT Margin for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 29.72%.

  • Neurocrine Biosciences' EBT Margin rose 38200.0% to 29.72% in Q4 2025 from the same period last year, while for Dec 2025 it was 24.66%, marking a year-over-year increase of 40300.0%. This contributed to the annual value of 24.66% for FY2025, which is 40300.0% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' EBT Margin stood at 29.72%, which was up 38200.0% from 36.71% recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' EBT Margin ranged from a high of 38.47% in Q4 2023 and a low of 24.57% during Q1 2023
  • Over the past 4 years, Neurocrine Biosciences' median EBT Margin value was 23.18% (recorded in 2023), while the average stood at 18.52%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 323900bps in 2021, then tumbled by -125700bps in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' EBT Margin stood at 10.3% in 2021, then skyrocketed by 273bps to 38.47% in 2023, then crashed by -33bps to 25.9% in 2024, then grew by 15bps to 29.72% in 2025.
  • Its last three reported values are 29.72% in Q4 2025, 36.71% for Q3 2025, and 23.2% during Q2 2025.